Caliway's CBL-514 Receives Early IND Clearance in China, Accelerating Development in the World's Fastest-Growing Body Contouring Market

Resumen detallado
Caliway Biopharmaceuticals (TWSE: 6919), a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced that its China clinical trial (CBL-0102) for CBL-514, the Company's first-in-class injectable drug candidate for large-area localized fat reduction, has officially received authorization to proceed from the Center for Drug Evaluation (CDE) of China's National Medical…
NEW TAIPEI CITY, Nov. 19, 2026 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919), a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics, announced that its China clinical trial (CBL-0102) for CBL-514, the Company's first-in-class injectable drug candidate for large-area localized fat reduction, has officially received authorization to proceed from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The program was independently developed and submitted by the Company, an achievement rarely accomplished by Taiwan biotechnology companies.
The trial is expected to begin subject enrollment in December 2026 and is planned to be completed in the second quarter of 2027, with clinical data expected shortly thereafter. Upon completion, the Company intends to promptly advance to the next stage of clinical development and regulatory submissions.
Accelerating Ethnicity Sensitivity Analysis to Strengthen Asian Development Strategy
In accordance with NMPA regulatory requirements, the CBL-0102 study is designed to evaluate ethnicity sensitivity in a Chinese population, assessing the potential impact of ethnic factors on the pharmacokinetic (PK) profile, safety, and tolerability of CBL-514 across different dose levels.
The clinical data generated from Asian subjects will not only provide important support for future pivotal Phase 3 studies and regulatory approval applications in China, but may also serve as a valuable reference for regulatory submissions across other Asian markets. The Company believes these data could support the broader development and commercialization strategy of CBL-514 throughout Asia.
CBL-0102 is a randomized, open-label, single-dose, parallel-design clinical study expected to enroll approximately 30 healthy subjects across two clinical sites in China.
Expanding CBL-514's Presence in China's RMB 643 Billion Body Contouring Market
China represents one of the world's…
Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)



